UK, US drugmakers scrap 'futile' Alzheimer's treatment trial

June 12, 2018

British and American pharmaceutical giants AstraZeneca and Eli Lilly on Tuesday said they were ending a large clinical trial of a treatment for Alzheimer's that they had been developing jointly.

The decision to scrap the phase III clinical trial comes as a major setback in the race to find a cure for the disease, which is the most common form of dementia and affects millions of people around the world.

With a clinical trial failure rate of over 99 percent, there is still no licenced drug that slows Alzheimer's progression or cures it.

"We are saddened by this outcome as our researchers are working tirelessly to find a solution for the many people who are impacted by this devastating disease," Menelas Pangalos, executive vice president of AstraZeneca said in a statement.

"We won't give up on finding a solution for Alzheimer's patients," Daniel Skovronsky, president of Lilly Research Labs added.

The two firms announced a partnership to develop a new drug aimed at combatting Alzheimer's in 2014.

They were working on two treatments—one for patients with early Alzheimer's disease, the other for those with mild Alzheimer's disease dementia.

Both treatments used a so-called "inhibitor" targeting an enzyme called BACE.

Multiple blows

According to the statement, an independent data monitoring committee ruled that both the treatments "were not likely to meet their primary end-points upon completion and therefore should be stopped for futility".

The statement also said the discontinuation of the trials was not expected to have any financial impact on the firms' outlook for 2018.

Health systems in Western countries are struggling to deal with Alzheimer's as it is costly to treat sufferers of the incurable disease which leaves them increasingly reliant on assistance.

US pharmaceutical behemoth Pfizer announced in January it was pulling out of neuroscience research entirely.

Swiss giants Roche and Axovant, as well US firm Merck have all tried unsuccessfully to come up with the solution to Alzheimer's.

According to the World Health Organization, some 50 million people around the world have dementia, with Alzheimer's accounting for 60-70 percent of the cases.

As the world's population ages, the number of patients is expected to double by 2030 and to triple by 2050 if no cure is found.

The global cost of caring for sufferers was set to reach $1 trillion (850 billion euros) this year.

According to the Alzforum website, which gathers data on candidate drugs, fewer than 300 have made it to Phase II trials so far.

Only five have ever been approved to treat symptoms such as memory loss associated with Alzheimer's, a disease first identified more than 100 years ago.

"Although dementia mainly affects older people, it is not a normal part of ageing," the WHO says on its website.

"Dementia has a physical, psychological, social, and economic impact, not only on people with dementia, but also on their carers, families and society at large," it adds.

Explore further: Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

Related Stories

Study predicts most people with earliest Alzheimer's signs won't develop dementia associated with the disease

May 22, 2018
During the past decade, researchers have identified new ways to detect the earliest biological signs of Alzheimer's disease. These early signs, which are detected by biomarkers, may be present before a person starts to exhibit ...

Merck halts trial of once 'promising' Alzheimer's drug

February 15, 2017
US pharmaceutical giant Merck announced it is halting a clinical trial on a drug once touted as a promising treatment for Alzheimer's disease, saying studies show it does not work.

New forecast shows 6 million with Alzheimer's disease, cognitive impairment

December 8, 2017
Using new methodology, scientists calculate that approximately 6 million American adults have Alzheimer's disease or mild cognitive impairment, which can sometimes be a precursor to the disease. The estimate, funded by the ...

Arthritis drugs linked to lower Alzheimer's risk

February 13, 2018
Scientists from the University of Southampton have teamed up with researchers from the University of Oxford to look at whether existing drugs for arthritis have any effect on a person's risk of developing dementia. By looking ...

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's drug targeting soluble amyloid falls short in a large clinical trial

January 25, 2018
A paper published today in the New England Journal of Medicine reports that solanezumab, a monoclonal antibody-based treatment for Alzheimer's disease developed by Eli Lilly that targets amyloid plaques, did not significantly ...

Recommended for you

Scientists discover why some people with brain markers of Alzheimer's have no dementia

August 16, 2018
A new study from The University of Texas Medical Branch at Galveston has uncovered why some people that have brain markers of Alzheimer's never develop the classic dementia that others do. The study is now available in the ...

Researchers identify new genes that may contribute to Alzheimer's disease

August 14, 2018
Researchers from Boston University School of Medicine, working with scientists across the nation on the Alzheimer's Disease Sequencing Project (ADSP), have discovered new genes that will further current understanding of the ...

Deaths from resident-to-resident incidents in dementia offers insights to inform policy

August 14, 2018
Analyzing the incidents between residents in dementia in long-term care homes may hold the key to reducing future fatalities among this vulnerable population, according to new research from the University of Minnesota School ...

Scientists propose a new lead for Alzheimer's research

August 14, 2018
A University of Adelaide-led team of scientists has suggested a potential link between iron in our cells and the rare gene mutations that cause Alzheimer's disease, which could provide new avenues for future research.

Eye conditions provide new lens screening for Alzheimer's disease

August 8, 2018
Alzheimer's disease is difficult to diagnose as well as treat, but researchers now have a promising new screening tool using the window to the brain: the eye.

Potential indicator for the early detection of dementias

August 7, 2018
Researchers at the University of Basel have discovered a factor that could support the early detection of neurodegenerative diseases such as Alzheimer's or Parkinson's. This cytokine is induced by cellular stress reactions ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.